PRIMARY RESULTS OF SUBCUTANEOUS EPCORITAMAB DOSE EXPANSION IN PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A PHASE 2 STUDY

EHA Library, Catherine Thieblemont, 366208

GENETIC AND EPIGENETIC FACTORS DRIVING PRIMARY MEDIASTINAL B-CELL LYMPHOMA PATHOGENESIS AND OUTCOME

EHA Library, Daniel Noerenberg, 356966

COMPREHENSIVE GENOME CHARACTERIZATION REVEALS NEW SUBTYPES AND MECHANISMS OF ONCOGENE DEREGULATION IN CHILDHOOD T-ALL

EHA Library, Petri Pölönen, 356967

EFFICACY AND SAFETY OF ARI0002H, AN ACADEMIC BCMA-DIRECTED CAR-T CELL THERAPY WITH FRACTIONATED INITIAL THERAPY AND BOOSTER DOSE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Carlos Fernández de Larrea, 356968

RBPS DYSREGULATION CAUSE HYPER-NUCLEOLI AND RIBOSOME GAIN-OF-FUNCTION DRIVING BONE MARROW FAILURE

EHA Library, Pedro Aguilar Garrido, 356969

QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML

EHA Library, Harry Erba, 356965

CD123-CD33 COMPOUND CAR-T CELLS WITH NOVEL ANTIGEN BINDING DOMAINS PROVIDE A NEW HOPE FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA

EHA Library, Zhenzhen Wang, 356985

ROCK INHIBITORS TARGET SRSF2 LEUKEMIA BY DISRUPTING CELL MITOSIS AND NUCLEAR MORPHOLOGY

EHA Library, Minhua Su, 356986

DECODING TRANSCRIPTOMIC AND EPIGENETIC CONSEQUENCES OF STRUCTURAL VARIANTS IN CK-AML AT SINGLE-CELL RESOLUTION

EHA Library, Aino-Maija Leppä, 356987

BONE MORPHOGENETIC PROTEIN 2 TRIGGERS OFF AN IMMUNOSUPPRESSIVE EFFECT OF ΓΔ T CELLS IN ACUTE MYELOID LEUKEMIA

EHA Library, Shuang Liang, 356988

BIOLOGY AND FUNCTION OF CIRCULAR PCMDT1 IN CHRONIC MYELOID LEUKEMIA IN BLAST CRISIS (CML-BC)

EHA Library, Amog Prathap Urs, 357014

HIGH-THROUGHPUT EVALUATION OF THE POTENTIAL OF CANCER DRUGS TO ENHANCE NATURAL KILLER CELL IMMUNOTHERAPY IN CHRONIC MYELOID LEUKEMIA.

EHA Library, Petra Nygren, 357015

SETD2/H3K36ME3 DEFICIENCY SUSTAINS GENOMIC INSTABILITY AND ENHANCES CLONOGENIC POTENTIAL OF CHRONIC MYELOID LEUKEMIA (CML) PROGENITORS

EHA Library, Manuela Mancini, 357016

DECRYPTING THE ROLE OF HSP90Α AND Β ISOFORMS TO OVERCOME RESISTANCE IN BCR-ABL1 LEUKEMIA

EHA Library, Melina Vogt, 357017

IMATINIB-RESISTANT CLONES ISOLATED FROM A MODEL OF BLAST CRISIS OF CHRONIC MYELOID LEUKAEMIA DIFFER IN MUTATIONS IN BCR::ABL1 AND OTHER CANCER RELATED GENES AND IN THEIR SENSITIVITY TO BH3-MIMETICS

EHA Library, Adam Laznicka, 357018

RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL

EHA Library, Caroline Hasselbalch Riley, 357044

MODAKAFUSP ALFA (TAK-573): UPDATED CLINICAL, PHARMACOKINETIC (PK), AND IMMUNOGENICITY RESULTS FROM A PHASE 1/2 STUDY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Jonathan L. Kaufman, 357045

TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED EFFICACY AND SAFETY RESULTS FROM MONUMENTAL-1

EHA Library, Monique C. Minnema, 357046

NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS FOR TALQUETAMAB (A GPRC5D X CD3 BISPECIFIC ANTIBODY) IN COMBINATION WITH DARATUMUMAB

EHA Library, Niels W C J van de Donk, 357047

EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS

EHA Library, Cyrille Touzeau, 357048

MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC AND ANEMIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR

EHA Library, Srdan Verstovsek, 357059

ROPEGINTERFERON ALFA-2B ACHIEVES PATIENT-SPECIFIC TREATMENT GOALS IN POLYCYTHEMIA VERA: FINAL RESULTS FROM THE PROUD-PV/CONTINUATION-PV STUDIES

EHA Library, Heinz Gisslinger, 357060

NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY

EHA Library, Francesco Passamonti, 357061

BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY

EHA Library, John Mascarenhas, 357062

A NATIONAL RETROSPECTIVE COHORT STUDY OF MPN-SVT: RESULTS FROM THE UK MYELOPROLIFERATIVE NEOPLASMS ASSOCIATED SPLANCHNIC VEIN THROMBOSIS (MASCOT) REGISTRY

EHA Library, Rupen Hargreaves, 357063

ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL

EHA Library, Pier Luigi Zinzani, 357069

OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM BENEFIT OVER RITUXIMAB PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: FINAL ANALYSIS OF THE GALLIUM STUDY

EHA Library, William Townsend, 357070

EFFICACY AND SAFETY OF A THIRD GENERATION CD20 CART (MB-106) FOR TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL)

EHA Library, Mazyar Shadman, 357071

EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING (ID) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF THE GLOBAL PHASE 2 STUDY TIDAL

EHA Library, Andrew Zelenetz, 357072

PRIMARY RESULTS FROM THE PHASE 3 SHINE STUDY OF IBRUTINIB IN COMBINATION WITH BENDAMUSTINE-RITUXIMAB (BR) AND R MAINTENANCE AS A FIRST-LINE TREATMENT FOR OLDER PATIENTS WITH MANTLE-CELL LYMPHOMA

EHA Library, Michael L. Wang, 357073

CAR T-CELLS ASSOCIATED ACUTE TOXICITY IN B-CELL NON-HODGKIN LYMPHOMA: REAL-WORLD STUDY FROM THE DESCAR-T REGISTRY

EHA Library, Pierre Sesques, 357074

CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (ZUMA-7)

EHA Library, Anna Sureda Balari, 357075

PHASE I STUDY OF YTB323, A CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY MANUFACTURED USING T-CHARGE™, IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Michael Dickinson, 357076

EFFICACY AND SAFETY OF HUMANIZED VERSUS MURINIZED CD19 AND CD22 CAR-T CELL COCKTAIL THERAPY FOR REFRACTORY/RELAPSED B-CELL LYMPHOMA

EHA Library, Peihua Lu, 357077

PHASE 1/2 STUDY OF ANBAL-CEL, NOVEL ANTI-CD19 CAR-T THERAPY WITH DUAL SILENCING OF PD-1 AND TIGIT IN RELAPSED OR REFRACTORY LARGE B CELL LYMPHOMA

EHA Library, Won Seog Kim, 357078

HUMAN ΒETA-DEFENSIN 2 TREATMENT MODULATES THE INTESTINAL MICROBIOME AND THE ALLOGENEIC T CELL RESPONSE TO LIMIT ACUTE GRAFT-VERSUS-HOST DISEASE

EHA Library, Tamina Rückert, 357094

GLUCOCORTICOID AND GLYCOLYSIS INHIBITORS COOPERATIVELY ABROGATE ACUTE GRAFT-VERSUS-HOST DISEASE

EHA Library, Zhengli Xu, 357095

EXPANDING THE REPERTOIRE OF HLA CLASS I-RESTRICTED MINOR HISTOCOMPATIBILITY ANTIGENS FOR IMMUNE MONITORING AND MODULATION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Kyra Fuchs, 357096

THERAPEUTIC GENE EDITING OF T CELLS CORRECTS CTLA4 INSUFFICIENCY.

EHA Library, Thomas Fox, 357097

CLINICAL-GRADE MBIL21/4-1BBL EXPANDED NK CELLS EXHIBIT STRONGER COMPETENCE COMPARED WITH PRIMARY NK CELLS AGAINST HCMV INFECTION

EHA Library, Qian-Nan Shang, 357098

EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) MATURE B-CELL NON-HODGKIN LYMPHOMA (NHL): THE PHASE II BIANCA STUDY

EHA Library, Veronique Minard-Colin, 357119

TABELECLEUCEL FOR EBV-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL OR SOLID ORGAN TRANSPLANT AFTER FAILURE OF RITUXIMAB ± CHEMOTHERAPY (ALLELE)

EHA Library, Susan Prockop, 357120

A PHASE 1, FIRST-IN-HUMAN, DOSE-ESCALATION CLINICAL TRIAL OF MEMORY-ENRICHED CD30-CAR T-CELL THERAPY FOR THE TREATMENT OF RELAPSED OR REFRACTORY HODGKIN LYMPHOMA AND CD30+ T-CELL LYMPHOMA

EHA Library, Ana Carolina Caballero, 357121

LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PRIMARY ANALYSIS FROM THE PHASE 2 PILOT STUDY

EHA Library, Alison Sehgal, 357122

DUAL ANTIGEN TARGETING WITH CO-TRANSDUCED CD19/22 CAR T CELLS FOR RELAPSED/REFRACTORY ALL

EHA Library, Sara Ghorashian, 357123

ATRA CAN CORRECT DEFECTIVE HIF-1Α/S1P AXIS-MEDIATED CYTOSKELETAL REORGANIZATION IN PROPLATELET FORMATION OF ITP

EHA Library, Qiu-Sha Huang, 357154

PHASE I/II STUDY OF RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR, IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: LONG-TERM FOLLOW-UP

EHA Library, David Kuter, 357155

SUSTAINED RESPONSE OFF TREATMENT IN ELTROMBOPAG-TREATED PATIENTS WITH ITP WHO ARE REFRACTORY OR RELAPSED AFTER FIRST-LINE STEROIDS: PRIMARY ANALYSIS OF THE PHASE II TAPER TRIAL

EHA Library, Nichola Cooper, 357156

RISK OF FRACTURES IN ADULT PATIENTS WITH PRIMARY AND SECONDARY IMMUNE THROMBOCYTOPENIA: A DANISH NATIONWIDE COHORT STUDY

EHA Library, Nikolaj Mannering, 357157

LONG-TERM SAFETY AND EFFICACY OF CAPLACIZUMAB FOR ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP): THE POST-HERCULES STUDY

EHA Library, Marie Scully, 357158

ACUTE MYELOID LEUKEMIA REPRESENTS A FERROPTOSIS-SENSITIVE CANCER ENTITY RAISING THE POSSIBILITY FOR NOVEL TARGETING STRATEGIES

EHA Library, Andreas Narr, 356984

GERMAN AMLCG-SURVIVORSHIP STUDY: QUALITY OF LIFE AND LIFE SATISFACTION IN AML LONG-TERM SURVIVORS

EHA Library, Eva Telzerow, 357165

COST-EFFECTIVENESS OF KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

EHA Library, Monia Marchetti, 357166

EFFECT OF PEGCETACOPLAN ON QUALITY OF LIFE IN COMPLEMENT-INHIBITOR NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE PHASE 3 PRINCE STUDY

EHA Library, David Gomez-Almaguer, 357167

SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, PROVIDES SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): 2 YEAR FOLLOW-UP FROM THE CARDINAL STUDY

EHA Library, Alexander Röth, 357168

HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD)

EHA Library, Mattia D'Agostino, 357164

A PHASE 2, OPEN-LABEL, ASCENDING DOSE STUDY OF KER-050 FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Shuhying Tan, 357638

LONG-TERM UTILIZATION AND BENEFIT OF LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) FROM THE MEDALIST TRIAL

EHA Library, Pierre Fenaux, 357640

OPTIMIZING TREATMENT OUTCOMES FOR CHILDREN WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Yuanyuan Ren, 357641

COMBINATION THERAPY OF ELTROMBOPAG AND CYCLOSPORINE A CAN IMPROVE HEMATOPOIESIS IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROME

EHA Library, Luxi Song, 357642

CLINICAL OUTCOMES AND HEALTHCARE RESOURCE UTILIZATION (HCRU) IN PATIENTS WITH LR-MDS REINITIATING ESAS FOLLOWING PREVIOUS ESA TREATMENT

EHA Library, Guillermo Garcia-Manero, 357643

SYSTEMIC THERAPY UTILIZATION AND HEMATOLOGIC OUTCOMES IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FINDINGS FROM A REAL-WORLD MEDICAL RECORD REVIEW STUDY IN THE US, UK, AND EUROPE (EU)

EHA Library, Aylin Yucel, 357645

A PHASE I/II STUDY OF VENETOCLAX IN COMBINATION WITH ASTX727 (DECITABINE/CEDAZURIDINE) IN TREATMENT‐NAÏVE HIGH‐RISK MYELODYSPLASTIC SYNDROME (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

EHA Library, Sangeetha Venugopal, 357646

CURRENT CARDIOVASCULAR DISEASE RISK PREDICTION MODELS ARE NOT APPLICABLE IN MDS PATIENTS: PRELIMINARY RESULTS OF A PROSPECTIVE OBSERVATIONAL SINGLE-CENTRE COHORT STUDY

EHA Library, Ioannis Kotsianidis, 357647

ANTI-PD-1 ANTIBODY (SINTILIMAB) PLUS DECITABINE AS FIRST LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME（MDS）: PRELIMINARY RESULTS FROM A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY

EHA Library, Jing Wang, 357648

FACTORS DRIVING TREATMENT DECISION IN PATIENTS WITH INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROME (MDS): A RETROSPECTIVE ANALYSIS FROM THE GRUPO ESPAÑOL DE SÍNDROMES MIELODISPLÁSICOS SPANISH MDS REGISTRY

EHA Library, María Díez Campelo, 357649

SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO-MYELOID CLINICAL TRIAL PROGRAM

EHA Library, Amer M. Zeidan, 357650

ANALYSIS OF THE CLINICAL FEATURES, PROGNOSIS AND GENE MUTATIONS IN PRIMARY MYELODYSPLASTIC SYNDROME PATIENTS WITH MYELOFIBROSIS

EHA Library, Gaixiang Xu, 357651

THE EXPRESSION LEVEL OF WT1 MRNA IN PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE (ICUS) PROGRESSING TO MYELODYSPLASTIC SYNDROME (MDS)

EHA Library, Xingnong Ye, 357652

COMMON VARIANTS IN COMPLEMENT PROTEINS, C3 AND CR1, ENHANCE COMPLEMENT ATTACK ON PNH ERYTHROCYTES AND INCREASE RISK FOR EXTRAVASCULAR HAEMOLYSIS

EHA Library, April Joy Baral, 357653

CRISPR/CAS9-BASED MODEL OF HETEROZYGOUS CXCR4 WT/R334X MUTATION TO STUDY CELLULAR PHENOTYPES IN WHIM SYNDROME

EHA Library, Katarina Zmajkovicova, 357654

SCREENING OF NATURALLY OCCURRING CXCR4 VARIANTS FOR IDENTIFICATION OF NOVEL PATHOGENIC MUTATIONS FOR WHIM SYNDROME

EHA Library, Sumit Pawar, 357655

CHARACTERIZATION OF ERCC6L2 SYNDROME PATIENTS' TRANSCRIPTOME

EHA Library, Suvi Douglas, 357657

ENRICHED CD16+ MONOCYTES DRIVE T LYMPHOCYTES CELL RESPONSES IN APLASTIC ANEMIA

EHA Library, Meili Ge, 357658

METABOLIC PROFILING IN ERCC6L2 AND SHWACHMAN DIAMOND SYNDROME

EHA Library, Ilse Kaaja, 357659

SPATIAL ANALYSIS IDENTIFIES A SPECTRUM OF IMMUNE DYSREGULATION IN ACQUIRED BONE MARROW FAILURE CONDITIONS

EHA Library, Rachel Koldej, 357661

BLOCKADE OF COMMON GAMMA CHAIN CYTOKINE SIGNALING WITH REGN7257, AN INTERLEUKIN 2 RECEPTOR GAMMA (IL2RG) MONOCLONAL ANTIBODY, PROTECTED MICE FROM GRAFT-VERSUS-HOST DISEASE AND IMMUNE APLASTIC ANEMIA

EHA Library, Audrey Le Floc'h, 357662

EVALUATION OF COMMON GAMMA CHAIN CYTOKINE SIGNALING BLOCKADE WITH REGN7257, AN INTERLEUKIN 2 RECEPTOR GAMMA (IL2RG) MONOCLONAL ANTIBODY, ON IMMUNE CELL POPULATIONS ACROSS SPECIES

EHA Library, Audrey Le Floc'h, 357663

PATTERNS OF T-CELL AUTOREACTIVITY DIFFER BETWEEN PEDIATRIC APLASTIC ANEMIA AND HEPATITIS-ASSOCIATED BONE MARROW FAILURE

EHA Library, Michaela Reiterová, 357664

TELOMERE SHORTENING IN BONE MARROW MESENCHYMAL STEM CELLS OF ACQUIRED APLASTIC ANEMIA PATIENTS ASSOCIATE WITH ALTERED EXPRESSION OF GENES INVOLVED IN TELOMERE MAINTENANCE, DNA DAMAGE, AND SENESCENCE

EHA Library, Jyotika Srivastava, 357665

EX VIVO TREATMENT WITH ELTROMBOPAG RESCUES HEMATOPOIETIC STEM CELLS FROM ANTI-THYMOCYTE GLOBULIN-RELATED DAMAGE DURING IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH APLASTIC ANEMIA

EHA Library, Margherita Vieri, 357666

ALEMTUZUMAB IN RELAPSED SEVERE APLASTIC ANEMIA: LONG-TERM RESULTS OF A PHASE II STUDY

EHA Library, Nidhi Aggarwal, 357667

IMPACT OF MARROW HEMOPHAGOCYTOSIS IN DIAGNOSTIC DEFINITION AND PROGNOSTIC SIGNIFICANCE IN ADULT POPULATION

EHA Library, Cátia Almeida, 357668

APLASTIC ANEMIA FOLLOWING THE SARS-COV-2 VACCINE

EHA Library, Rodrick Babakhanlou, 357669

CONGENITAL NEUTROPENIA PREVALENCE AMONG POLISH CHILDREN – SUMMARY OF A NATIONWIDE GENETIC SCREENING CAMPAIGN

EHA Library, Katarzyna Bąbol-Pokora, 357670

MODULATION OF ARACHIDONIC ACID PATHWAY BY IBUPROFEN RESULTS IN COMPLETE HEMATOLOGICAL RESPONSE IN GHOSAL HEMATODIAPHYSEAL DYSPLASIA WITHOUT NEED FOR CORTICOSTEROID

EHA Library, Neil Barrett, 357671

BONE MARROW FAILURE IN PATIENTS CARRYING VARIANTS ON CARD11 GENE.

EHA Library, Andrea Beccaria, 357672

A SINGLE CENTER HISTORICAL CONTROL STUDY OF ELTROMBOPAG ADDED TO IMMUNOSUPPRESSIVE THERAPY FOR SEVERE APLASTIC ANEMIA IN CHILDREN

EHA Library, Bixi Yang, 357673

LONG-TERM COMPLEMENT INHIBITION AND SURVIVAL OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: AN INTERIM ANALYSIS OF THE RAVULIZUMAB CLINICAL TRIALS

EHA Library, Austin Kulasekararaj, 357674

EFFICACY, TREATMENT ADMINISTRATION SATISFACTION AND SAFETY OF SUBCUTANEOUS RAVULIZUMAB THROUGH 1 YEAR IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED PRIOR INTRAVENOUS ECULIZUMAB

EHA Library, Mustafa N. Yenerel, 357675

CLINICAL CHARACTERISTICS AND GENE MUTATION ANALYSIS OF 148 CHILDREN WITH FANCONI ANEMIA IN CHINA

EHA Library, Lixian Chang, 357676

PHARMACOKINETIC AND PHARMACODYNAMIC SIMILARITY OF ABP 959 AND ECULIZUMAB REFERENCE PRODUCT: UNBOUND ECULIZUMAB AND CH50 FROM THE RANDOMIZED, DOUBLE-BLIND, SINGLE-DOSE STUDY IN HEALTHY VOLUNTEERS

EHA Library, Vincent Chow, 357677

TRANSIENT MONOSOMY 7 IN SAMD9/9L SYNDROMES: IS IT SAFE TO WATCH AND WAIT?

EHA Library, Miriam Erlacher, 357678

SYNDROMES PREDISPOSING TO LEUKEMIA ARE A MAJOR CAUSE OF INHERITED CYTOPENIAS IN CHILDREN

EHA Library, Oded Gilad, 357679

NEXT GENERATION TARGETED SEQUENCING FOR ENHANCED GENOTYPING OF DIAMOND BLACKFAN ANEMIA IN ISRAEL

EHA Library, Tracie Goldberg, 357680

TRANSPLANT, TREATMENT AND TRANSFUSION FREE (TTT-FREE) SURVIVAL AS RELEVANT CLINICAL ENDPOINT AFTER IMMUNOSUPPRESSIVE TREATMENT FOR ACQUIRED APLASTIC ANEMIA IN ADULTS

EHA Library, CJM Halkes, 357681

PREDICTING RESPONSE TO RABBIT ATG-BASED INTENSIVE IMMUNOSUPPRESSIVE THERAPY COMBINED WITH ELTROMBOPAG IN CHINESE ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA

EHA Library, Guangsheng He, 357682

AN AUDIT OF PAIN EDUCATION IN PATIENTS WITH SICKLE CELL DISEASE

EHA Library, Yuhui Zhou, 358361

IS IRON OVERLOAD ASSOCIATED WITH WORSE OUTCOMES IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING LIVER TRANSPLANT?

EHA Library, Sergio Rodriguez-Rodriguez, 358418

CLINICAL OUTCOMES AND SOCIOECONOMIC FACTORS IN CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE UNITED STATES USING THE NATIONAL CANCER DATABASE: 2004-2017

EHA Library, Nicole Mclaughlin, 357637